진행성 또는 전이성 위암 환자에 있어서 Oxaliplatin 투여로 인한 말초신경통증 분석Oxaliplatin-induced Peripheral Neuropathy in Patients with Advanced or Metastatic Gastric Cancer
- Other Titles
- Oxaliplatin-induced Peripheral Neuropathy in Patients with Advanced or Metastatic Gastric Cancer
- Authors
- 박애령; 방준석; 김순주; 나현오
- Issue Date
- Jun-2009
- Publisher
- 한국임상약학회
- Keywords
- gastric cancer; oxaliplatin; peripheral neuropathy; modified FOLFOX-6
- Citation
- 한국임상약학회지, v.19, no.1, pp 18 - 22
- Pages
- 5
- Journal Title
- 한국임상약학회지
- Volume
- 19
- Number
- 1
- Start Page
- 18
- End Page
- 22
- URI
- https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/148048
- ISSN
- 1226-6051
2508-786X
- Abstract
- Oxaliplatin is a tolerable and effective drug of choice in the treatment of advanced or metastatic gastric cancer. However, it has many dose-limiting neurotoxicities. This study was performed to assess the incidence and types of oxaliplatin-related neurotoxicities. Sixty-four patients receiving oxaliplatin-involved regimen as salvage therapy on metastatic gastric cancer or as the first-line therapy on advanced gastric cancer were evaluated during the period between September 1, 2006 and February 29, 2008. The patients were treated with oxaliplatin 100 mg/m2 and leucovorin 100 mg/m2 simultaneously as 2-hour-lasting infusion on Day-1 followed by 5-FU 1200 mg/m2 as a 22-hour-lasting continuous infusion both on Day-1 and Day-2 by every other week. We developed questionnaires to evaluate patient-recognized neurotoxic
symptoms rather than the observer-described events. Surveys were completed at bedside or via telephone interview. Acute and chronic neurotoxicities were graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC, version 3) as well as the Oxaliplatin-specific Neurotoxicity Scale. The Grade-3 neuropathy was reported in 19% of the patients (n=12) and grade-1/2 neuropathy occurred in 70% (n=45). The most common symptom was cold-related dysesthesia (83%) regarded as nociperception by the patients. Some patients (19%) experienced
functional impairment affecting activities of daily living such as writing, buttoning, and walking. Even though 74% of the patients (42/57) were prescribed with gabapentin to reduce these peripheral symptoms, it did not appear to derive any benefit from this medication. It is suggested that notify the patients about their oxaliplatin-associated, debilitating symptoms, and educate them any self-care strategy at the initiating phase of the chemotherapy. Moreover, it needs to design the intervention studies regarding the prevention and management of the peripheral neuropathy.
- Files in This Item
-
Go to Link
- Appears in
Collections - 약학대학 > 약학부 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.